ClinicalTrials.Veeva

Menu
A

ASST Papa Giovanni XXIII | Ospedale di Bergamo - SC Malattie Endocrine-Diabetologia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nivolumab
Atezolizumab
Finerenone
Odevixibat
Pembrolizumab
Gemcitabine
Carboplatin
Vericiguat
Avelumab
Ipilimumab

Parent organization

This site is a part of ASST Papa Giovanni XXIII

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 94 total trials
Locations recently updated

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults wit...

Enrolling
Hypertension, Pulmonary
Drug: Placebo
Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Locations recently updated

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)
Locations recently updated

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve U...

Enrolling
Melanoma
Drug: ABP 206
Drug: Nivolumab

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPD...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278
Locations recently updated

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Enrolling
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progressi...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Paclitaxel
Drug: Nivolumab

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Invitation-only
Biliary Atresia
Drug: Odevixibat

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order...

Enrolling
Renal Carcinoma Metastatic
Drug: Axitinib Oral Tablet
Drug: Avelumab

The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participa...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with...

Active, not recruiting
Biliary Atresia
Drug: Odevixibat
Drug: Placebo

The goal of the study is to investigate the efficacy and safety of Lenodiar Pediatric (product under investigation) for the treatment of Chronic Diar...

Enrolling
Chronic Diarrhoea of Infants and/or Young Children
Device: Lenodiar Pediatric
Other: Placebo

POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combinat...

Enrolling
Breast Cancer Recurrent
Drug: Standard endocrine therapy
Drug: Palbociclib 125mg

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in m...

Enrolling
Non-Small Cell Lung Cancer Metastatic
Gastric Cancer
Drug: MCLA-129
Drug: Osimertinib

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Pembrolizumab

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembro...

Active, not recruiting
Malignant Melanoma
Drug: Lenvatinib
Drug: Placebo for lenvatinib

Trial sponsors

Bayer logo
Bristol-Myers Squibb (BMS) logo
Roche logo
Merck Sharp & Dohme (MSD) logo
Novo Nordisk logo
M
Gilead Sciences logo
Amgen logo
I
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems